June 24, 2017 11:26 PM ET

Pharmaceuticals

Company Overview of Tarsa Therapeutics, Inc.

Company Overview

Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.

1628 John F. Kennedy Boulevard

8 Penn Center

Suite 1400

Philadelphia, PA 19103-2124

United States

Founded in 2009

Phone:

267-273-7940

Fax:

267-273-7950

Key Executives for Tarsa Therapeutics, Inc.

Founder, Chief Executive Officer, President and Director
Founder and Chief Scientific Officer
Age: 64
Chief Medical Officer
Age: 67
Vice President of CMC & Supply
Age: 60
Vice President of Global Regulatory Affairs
Age: 60
Compensation as of Fiscal Year 2016.

Tarsa Therapeutics, Inc. Key Developments

TARSA Therapeutics' NDA For TBRIA, The First Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis, Accepted For Filing

TARSA Therapeutics Inc. announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016. Calcitonin has been available as an osteoporosis treatment for more than 35 years, but only in formulations allowing for injectable or intranasal administration. TBRIA would be the first FDA approved oral calcitonin, offering a convenient route of administration and potentially providing enhanced patient acceptance and compliance. TBRIA is a once-daily oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). TBRIA demonstrated positive safety and efficacy as a treatment for postmenopausal osteoporosis in the global, randomized, double-blind ORACAL trial. This study, which was the subject of a Special Protocol Assessment with the FDA, is the pivotal Phase III trial that forms the basis for TARSA's NDA. In the trial, TBRIA met its primary endpoint and demonstrated statistical superiority to both placebo and nasal calcitonin spray in increasing bone mineral density at the lumbar spine after 48 weeks of use. The safety profile of TBRIA did not substantially differ from nasal calcitonin or placebo. Study results were published in the Journal of Bone and Mineral Research.

Tarsa Therapeutics, Inc Presents at Sofinnova Japan Biopharma Partnering Conference 2015, Oct-27-2015 03:30 PM

Tarsa Therapeutics, Inc Presents at Sofinnova Japan Biopharma Partnering Conference 2015, Oct-27-2015 03:30 PM. Venue: Conrad Hotel, 1-9-1, Higashi-Shinbashi, Minato-Ku, Tokyo, 105 7337, Japan.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 29, 2016
--
Private Placement
June 29, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tarsa Therapeutics, Inc., please visit www.tarsatherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.